EyePoint, Inc. Accrued Liabilities for Commissions, Expense and Taxes
EyePoint, Inc. (EYPT) had Accrued Liabilities for Commissions, Expense and Taxes of $0 as of 2023-06-30, per its 10-Q filed 2023-08-04.
Discontinued › Notes
us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes · last filed 2023-08-04
- 2023-06-30: Accrued Liabilities for Commissions, Expense and Taxes $0.00.
- 2023-03-31: Accrued Liabilities for Commissions, Expense and Taxes $249.00K.
- 2022-12-31: Accrued Liabilities for Commissions, Expense and Taxes $752.00K.
- 2022-09-30: Accrued Liabilities for Commissions, Expense and Taxes $1.36M.
| Period end | Accrued Liabilities for Commissions, Expense and Taxes |
|---|---|
| 2023-06-30 | $0.00 10-Q · filed 2023-08-04 |
| 2023-03-31 | $249.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $752.00K 10-Q · filed 2023-08-04 |
| 2022-09-30 | $1.36M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $1.84M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $1.57M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $1.52M 10-K · filed 2023-03-10 |
| 2021-09-30 | $1.46M 10-Q · filed 2021-11-05 |
| 2020-12-31 | $254.00K 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |